Global Pediatric Vaccines Market 2023 Outlook By Product, Trends and Forecast To 2024-2032

Pediatric Vaccines Market Size And Forecast

Pediatric Vaccines Market size was valued at USD 34.6 Billion in 2021 and is projected to reach USD 83.7 Billion by 2030, growing at a CAGR of 10.3% from 2023 to 2030.

The rising popularity of technology-driven platforms for self-growth amongst millennials is also expected to positively impact market growth during the forecast period. Increasing awareness regarding vaccines and immunization among the populace is expected to boost the growth of the Global Pediatric Vaccines Market over the forecast period. A comprehensive analysis of the market is provided by the Global Pediatric Vaccines Development Market study. The research provides a thorough analysis of the market’s key segments, trends, drivers, restraints, competitive environment, and other important elements.

Global Pediatric Vaccines Market Definition

Infants must receive vaccinations to ward off illnesses including pneumonia, polio, and influenza. Through imitating a specific pathogen (infection-causing organism), vaccinations stimulate the immune system to manufacture the necessary antibodies, which eventually help the body acquire resistance against diseases brought on by these pathogens.

Some vaccines only include a little portion of a pathogen. Other vaccinations include instructions for your cells to produce a germ protein. According to National Centre for Disease Control (NCDC), In 2019, little over half of the children aged 60 days to 17 years had received a flu vaccine in the previous 12 months (53.1 percent). In general, and for each race and Hispanic-origin group studied, influenza vaccination coverage decreased as people got older. Children in more rural locations showed lower influenza vaccine coverage than those in metropolitan areas across all age groups. In the United States, the percentage of children who had received an influenza vaccine in the previous 12 months ranged from 47.9% in the East South-Central region to 65.3 percent in the New England region.

For each race and Hispanic-origin group, influenza vaccination rates fell with age, while percentages were equal for the two lower age groups among non-Hispanic black children. Non-Hispanic black children (48.9%) had poorer influenza vaccine coverage than non-Hispanic white children (64.1%) and Hispanic children (60.6%) among children aged 6 months to 4 years. The difference between non-Hispanic black children aged 5–11 years (47.8%), non-Hispanic white children (54.2%), and Hispanic children (54.8%) were not significant. Non-Hispanic black children (37.7%) had lower influenza vaccination coverage than non-Hispanic white children (45.8%) and Hispanic children (49.8%) among children aged 12–17 years.

Global Pediatric Vaccines Market Overview

The potential for new infectious diseases to spread swiftly and produce worldwide epidemics is a serious issue as people travel much more frequently and over much greater distances than in the past, live in more densely populated places, and come in closer contact with wild animals. Furthermore, diseases could occur as a result of the purposeful introduction of pathogens into human, animal, or plant populations for terrorist goals. Anthrax, smallpox, and tularemia are among these diseases. SARS, MERS, Ebola, dengue, bird influenza, swine flu, Zika, and, latest newly, COVID-19, which is caused by the SARS-CoV-2 coronavirus, have all been discovered since the 1970s. Future pandemics and outbreaks, experts warn, might be even more deadly than COVID-19.

The development of children’s immune systems to combat major illnesses and diseases like measles, diphtheria, poliomyelitis, and Haemophilus influenzae type b is greatly aided by pediatric immunizations (Hib). Pediatric immunizations are administered to kids between the ages of 0 and 18. Children who receive pediatric vaccinations at an early age are better able to defend themselves against a variety of infectious diseases. Numerous dangerous childhood disorders are now rare thanks to pediatric immunization.

The HPV vaccine and routine cervical screenings can help prevent cervical cancer. The American Cancer Society predicts that in 2020, there will be around 13,800 new instances of invasive cervical cancer diagnosed in the U.S., and 4,290 women are predicted to lose their lives to the disease. Between the ages of 9 and 12, the American Academy of Pediatrics advises HPV immunization for both boys and girls since the vaccine is most effective before exposure to the virus. Rising healthcare awareness and significant pharmaceutical company investment in the R&D of novel vaccines are further factors that are anticipated to drive the market’s expansion.

For instance, two Phase III studies of PCV-15 (V114), an experimental polyvalent conjugate vaccine for the prevention of pneumococcal illness, were started in April 2018 by Merck & Co, Inc. The limitations, including onerous government restrictions for the approval process and hefty costs, may prove to be a significant barrier to market expansion. Only one or two suppliers provide the majority of vaccines. Due to the enormous expenditure required to manufacture a vaccine, there are frequently notably few providers for more recent vaccines. The price of vaccines consequently rises as a result.

Another emerging-market trend is the increased need for low-cost vaccinations. To expand the reach of immunization programs in these economies, companies are investing in and focusing on creating inexpensive, low-cost vaccines. Antigens (poly or oligosaccharides) are chemically linked to the carrier protein in conjugate vaccinations. Polysaccharides are converted to T-dependent antigens by attaching them to protein, which triggers powerful immunological responses in newborns and adults. T-cells assist B-cells in producing IgG antibodies to the conjugated polysaccharide in these “glycoconjugate” vaccines.

Global Pediatric Vaccines Market: Segmentation Analysis

The Global Pediatric Vaccines market is segmented on the basis of Type, Technology, Application, And Geography.

Pediatric Vaccines Market, By Type

• Monovalent
• Multivalent

Based on Type, The market is divided into Monovalent and Multivalent. Monovalent or Polyvalent vaccines are available. A Monovalent vaccination is made out of only one antigen strain (e.g., Measles vaccine). A Polyvalent or Multivalent vaccination, on the other hand, comprises two or more antigen strains/serotypes (e.g., OPV). A large range of viruses have been studied as single-pathogen vector vaccines, but surprisingly few have been employed in Multivalent and multi-pathogen applications. Viruses must meet several criteria to be designated multi pathogens or Multivalent vectors. To boost humoral and cellular immune responses, the viral vector must be capable of taking up significant portions of immunogenic genes, as well as regulatory elements (e.g., promoter, polymerase, terminator, etc.) or immunomodulators like cytokines.

Pediatric Vaccines Market, By Technology

• Live Attenuated
• Inactivated
• Subunit
• Toxoid
• Conjugate
• Others

Based on Technology, The market is divided into Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate, and Others. A live-attenuated vaccine uses a virus that is still alive but has been weakened or a virus that is very similar to it. This type of vaccine includes the measles, mumps, and rubella (MMR) vaccine as well as the chickenpox and shingles vaccine. This method uses the same technology as the inactivated vaccine and allows for large-scale production. Vaccines (e.g., live attenuated, recombinant) and vaccine manufacturing methods (e.g., in ovo, cell culture) have evolved in lockstep. As vaccine technology has progressed, so have the means for producing vaccines, and new vaccination prospects have arisen. As we strive for safer and more immunogenic vaccines, and as our understanding of biology increases, these technologies will continue to evolve.

Pediatric Vaccines Market, By Application

• Infectious Disease
• Cancer
• Allergy

Based on Application, The market is divided into Infectious Disease, Cancer, and Allergy. mRNA vaccines have a lot of promise and have a lot of advantages over traditional vaccines. Preclinical and clinical evidence suggests that mRNA prophylaxis and therapy could be effective for preventing infectious disease and treating malignancies, and that mRNA vaccine mRNA vaccines are safe and well-tolerated in animal models and humans. Future enhancements should also boost antigen-specific immune responses as well as the size of memory immune cell responses, such as memory B and T cell responses. Even though the fact that mRNA vaccine technology has yet to be substantially tested in humans, preclinical and early clinical investigations have been published in recent years, with encouraging findings. This sparked a surge of interest among biotech companies to develop mRNA vaccines.

Pediatric Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, The Global Pediatric Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. During the projected period, North America is anticipated to account for the biggest market share. Its dominance can be linked to a number of important factors, including an increase in R&D expenditures by several businesses and a surge in government support for immunization and the creation of pediatric vaccines. Additionally, the expansion of this market is supported by the availability of modern healthcare infrastructure and immunization facilities.

Key Players

The “ Global Pediatric Vaccines Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as GlaxoSmithKline plc, Merck Sharp & Dohme Corp., SANOFI, AstraZeneca, Pfizer Inc., Zydus Cadila, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Mitsubishi Tanabe Pharma Corporation, and Panacea Biotec are some of the prominent market participants. Key development strategies, market share analysis, and market positioning analysis of the aforementioned competitors internationally are also included in the competitive landscape section.

Key Developments

Mergers and Acquisitions

• In April 2019, Merck Sharp & Dohme Corp. completed the acquisition of Immune Design for nearly $300 million, gaining access to its immunotherapy programs and In June 2019, Merck announced it would acquire Tilos Therapeutics for up to $773 million.

Product Launches and Product Expansions

• In 2019, Soligenix, Inc. initiated the study to assess the Safety of RiVax, a lyophilized ricin toxin A-chain subunit vaccine with alum-adjuvant.
• Two Phase III studies of PCV-15 (V114), an experimental polyvalent conjugate vaccination for the avoidance of pneumococcal illness, were started in April 2018 by Merck & Co, Inc.
• In 2017, Zydus Cadila received approval to launch the tetravalent inactivated influenza vaccine. A new product launch will develop the company’s product portfolio thereby generating enormous profits.
• The ERVEBO or Zaire Ebola virus vaccine V920 was approved by the U.S. FDA in December 2019 for NewLink Genetics Corporation.

Report Scope

Top Trending Reports

Research Methodology of Market Research:

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.